Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2016-08-28T10:08:17Z | - |
dc.date.available | 2016-08-28T10:08:17Z | - |
dc.date.issued | 2013 | * |
dc.identifier.issn | 0939-5555 | * |
dc.identifier.other | OAK-9641 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/223335 | - |
dc.description.abstract | Core binding factor (CBF)-positive acute myeloid leukemia (AML) presents a favorable prognosis, except for patients with KIT mutation, especially D816 mutation. The current retrospective study attempted to validate a prognostic role of KIT mutation in 121 Korean patients with CBF AML. The study patients consisted of 121 patients with CBF AML (82 patients with RUNX1/RUNX1T1 [67.8 %] and 39 patients with CBFB/MYH11 [32.2 %]) recruited from eight institutions in Korea. All patients received idarubicin plus cytarabine or behenoyl cytosine arabinoside 3 + 7 induction chemotherapy. The KIT gene mutation status was determined by direct sequencing analyses. A KIT mutation was detected in 32 cases (26.4 %) in our series of patients. The KIT mutation was most frequent in exon 17 (n = 18, 14.9 %; n = 16 with D816 mutation), followed by exon 8 (n = 10, 8.3 %). The presence of KIT D816 mutation was associated with adverse outcomes for the event-free survival (p = 0.03) and for the overall survival (p = 0.02). The unfavorable impact of D816 mutation was more prominent when the analysis was confined to the RUNX1/RUNX1T1 subtype. The KIT mutation was detected in 26.4 % of Korean patients with CBF AML. The KIT D816 mutation demonstrated an unfavorable prognostic implication, particularly in the RUNX1/RUNX1T1 subtype. © 2012 Springer-Verlag Berlin Heidelberg. | * |
dc.language | English | * |
dc.title | KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 92 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 163 | * |
dc.relation.lastpage | 171 | * |
dc.relation.journaltitle | Annals of Hematology | * |
dc.identifier.doi | 10.1007/s00277-012-1580-5 | * |
dc.identifier.wosid | WOS:000313445100003 | * |
dc.identifier.scopusid | 2-s2.0-84872345873 | * |
dc.author.google | Kim H.-J. | * |
dc.author.google | Ahn H.K. | * |
dc.author.google | Jung C.W. | * |
dc.author.google | Moon J.H. | * |
dc.author.google | Park C.-H. | * |
dc.author.google | Lee K.-O. | * |
dc.author.google | Kim S.-H. | * |
dc.author.google | Kim Y.-K. | * |
dc.author.google | Sohn S.K. | * |
dc.author.google | Kim S.H. | * |
dc.author.google | Lee W.S. | * |
dc.author.google | Kim K.H. | * |
dc.author.google | Mun Y.-C. | * |
dc.author.google | Kim H. | * |
dc.author.google | Park J. | * |
dc.author.google | Min W.-S. | * |
dc.author.google | Kim D.H.D. | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |